- Home
- RMM vs RLMD Comparison
RMM vs RLMD Comparison
Compare RMM & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMM | RLMD |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 307.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMM | RLMD |
|---|---|---|
| Price | $13.92 | $4.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 66.5K | ★ 2.2M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.32 | $0.24 |
| 52 Week High | $16.10 | $5.12 |
Technical Indicators
Market Signals| Indicator | RMM | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 77.33 |
| Support Level | $13.73 | $3.86 |
| Resistance Level | $13.92 | $4.38 |
| Average True Range (ATR) | 0.15 | 0.57 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 30.66 | 75.10 |
Price Performance
Historical ComparisonAbout RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.